Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALISON phase 1 study of vididencel after primary treatment in high-grade serous ovarian cancer
NL-OMON59513Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2024
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vididencel in ovarian cancer, sponsored by University Medical Center Groningen. Primary endpoint: Primary endpoint(s). Started Sep 2024; status: completed.
02
Drugs
vididencel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NL-OMON59513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59513.